The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2019

Filed:

Mar. 13, 2013
Applicant:

Michael Har-noy, Modi'in, IL;

Inventor:

Michael Har-Noy, Modi'in, IL;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/17 (2013.01); C12N 5/0638 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/57 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01);
Abstract

A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient.


Find Patent Forward Citations

Loading…